IRS1 and colonic neoplasm: Insulin resistance may contribute to chemotherapy resistance in individuals with colon cancer; as such, two colon cancer cell lines were used to determine whether the expression of IRS‐1 would affect the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment (Figure 1A).